Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Malignancy

¹Department of Surgery, University of Cincinnati Medical Center, Ohio.

The Surgical Clinics of North America

|October 1, 1994

Summary

This summary is machine-generated.

Organ transplant recipients rarely develop cancer, and the risk is not a contraindication. Non-renal transplant patients may face higher risks of life-threatening tumors due to intense immunosuppression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Depressed immunity and skin cancer.

Immunology today·2014

Same author

Immunosuppression and Neoplasia.

Behring Institute Mitteilungen·2010

Same author

Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting.

International journal of cardiovascular interventions·2003

Same author

Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina.

Circulation·2002

Same author

Some problems with posttransplant lymphoproliferative disease.

Transplantation·2001

Same author

HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients.

Gynecologic oncology·2000

Same journal

Social Determinants of Health, Health Disparities, and Surgical Equity.

The Surgical clinics of North America·2026

Same journal

Beyond the Scalpel's Reach.

The Surgical clinics of North America·2026

Same journal

Stepwise Solutions-Society.

The Surgical clinics of North America·2026

Same journal

Stepwise Solutions-Hospitals.

The Surgical clinics of North America·2026

Same journal

Stepwise Solutions for Providers.

The Surgical clinics of North America·2026

Same journal

Stepwise Solutions-Patients Social Determinants of Health, Health Disparities, and Surgical Equity.

The Surgical clinics of North America·2026

See all related articles

Area of Science:

Oncology
Transplantation Medicine
Immunology

Background:

Cancer is a known complication following organ transplantation.
Most organ allograft recipients do not develop de novo malignancies.
The risk of malignancy is generally not a contraindication for transplantation.

Purpose of the Study:

To analyze the incidence and types of de novo malignancies in organ transplant recipients.
To compare cancer risk between renal and non-renal allograft recipients.
To investigate the role of immunosuppressive therapy in post-transplant cancer development.

Main Methods:

Review of de novo malignancy development in organ allograft recipients.
Comparison of malignancy patterns in renal versus non-renal allograft recipients.

Related Experiment Videos

Correlation of immunosuppressive therapy intensity with tumor development.

Main Results:

The majority of organ transplant recipients do not develop cancer.
Common malignancies include treatable in situ carcinomas (cervix, vulva, perineum) and skin tumors.
Non-renal allograft recipients show a higher propensity for life-threatening tumors, particularly lymphomas.
Intense immunosuppression in non-renal recipients may contribute to increased cancer risk.

Conclusions:

De novo malignancy is a manageable complication in most organ transplant recipients.
Non-renal allograft recipients may require closer monitoring for potentially severe tumors.
Immunosuppression management is critical in mitigating cancer risk after transplantation.